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Introduction
Chromosome dynamics in eukaryotes are controlled by the struc-
tural maintenance of the chromosome complex (SMC) family 
of proteins, which form 3 highly conserved and functional com-
plexes: cohesin (SMC1/SMC3), condensin (SMC2/SMC4), and 
SMC5/6 (1). The SMC5/6 complex, consisting of SMC5, SMC6, 
and non-SMC elements NSMCE1–6, has key roles in the mainte-
nance of chromosome integrity during mitotic proliferation, mei-
osis, and DNA repair and is critical for genome stability (2–4). In 
particular, the SMC5/6 complex is involved in resolving interme-
diates during recombination (5, 6) and other complex DNA struc-
tures, such as stalled replication forks (7–9).
Recently, patients with primordial dwarfism, extreme insulin 
resistance, gonadal failure, and signs of mild spontaneous chromo-
some instability were identified as carrying mutations in NSMCE2, 
which encodes the SUMO ligase subunit of the SMC5/6 complex 
(10). Here, we report on patients with very different clinical fea-
tures carrying mutations in NSMCE3 (also known as NDNL2 and 
MAGEG1; OMIM *608243) (11–13), encoding another SMC5/6 
subunit, a member of the melanoma-associated antigen (MAGE) 
protein family (14, 15). Homozygous and compound heterozygous 
mutations were found in 2 independent kindreds, in which 4 chil-
dren died in early childhood after developing rapidly progressive 
pulmonary disease following viral pneumonia. The presence of 
multiple de novo chromosome rearrangements and variable num-
bers of de novo supernumerary marker chromosomes in peripheral 
blood lymphocytes during critical illness together with combined 
T and B cell immunodeficiency seen in these patients indicates an 
essential role for the SMC5/6 complex for normal human lympho-
cyte development and function. These findings extend the spec-
trum of the previously known chromosome breakage syndromes.
Results
The probands of the first kindred were 2 sisters from distantly 
related, healthy Dutch parents of European descent (Figure 1A, 
Table 1, Supplemental Figure 1, and Supplemental Data, Fam-
The structural maintenance of chromosomes (SMC) family of proteins supports mitotic proliferation, meiosis, and DNA 
repair to control genomic stability. Impairments in chromosome maintenance are linked to rare chromosome breakage 
disorders. Here, we have identified a chromosome breakage syndrome associated with severe lung disease in early childhood. 
Four children from two unrelated kindreds died of severe pulmonary disease during infancy following viral pneumonia with 
evidence of combined T and B cell immunodeficiency. Whole exome sequencing revealed biallelic missense mutations in the 
NSMCE3 (also known as NDNL2) gene, which encodes a subunit of the SMC5/6 complex that is essential for DNA damage 
response and chromosome segregation. The NSMCE3 mutations disrupted interactions within the SMC5/6 complex, leading 
to destabilization of the complex. Patient cells showed chromosome rearrangements, micronuclei, sensitivity to replication 
stress and DNA damage, and defective homologous recombination. This work associates missense mutations in NSMCE3 with 
an autosomal recessive chromosome breakage syndrome that leads to defective T and B cell function and acute respiratory 
distress syndrome in early childhood.
Destabilized SMC5/6 complex leads to chromosome 
breakage syndrome with severe lung disease
Saskia N. van der Crabben,1 Marije P. Hennus,2 Grant A. McGregor,3 Deborah I. Ritter,4 Sandesh C.S. Nagamani,5,6 Owen S. Wells,3 
Magdalena Harakalova,1 Ivan K. Chinn,6,7 Aaron Alt,3 Lucie Vondrova,8 Ron Hochstenbach,1 Joris M. van Montfrans,9  
Suzanne W. Terheggen-Lagro,10 Stef van Lieshout,1 Markus J. van Roosmalen,1 Ivo Renkens,1 Karen Duran,1 Isaac J. Nijman,1 
Wigard P. Kloosterman,1 Eric Hennekam,1 Jordan S. Orange,6,7 Peter M. van Hasselt,11 David A. Wheeler,4,5 Jan J. Palecek,8  
Alan R. Lehmann,3 Antony W. Oliver,3 Laurence H. Pearl,3 Sharon E. Plon,4,5,6,7 Johanne M. Murray,3 and Gijs van Haaften1
1Department of Genetics (Center for Molecular Medicine) and 2Department of Pediatric Intensive Care, Wilhelmina Children’s Hospital, University Medical Center Utrecht (UMCU),  
Utrecht, Netherlands. 3Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, United Kingdom. 4Human Genome Sequencing Center,  
5Department of Molecular and Human Genetics, 6Texas Children’s Hospital, and 7Department of Pediatrics, Baylor College of Medicine, Houston Texas, USA. 8Central European Institute of Technology and 
Faculty of Science, Masaryk University, Brno, Czech Republic. 9Department of Pediatric Immunology and Infectious Diseases, 10Department of Pediatric Pulmonary Diseases, and  
11Department of Metabolic Diseases, Wilhelmina Children’s Hospital, UMCU, Utrecht, Netherlands.
Authorship note: S.N. van der Crabben, M.P. Hennus, G.A. McGregor, and D.I. Ritter 
contributed equally to this work. S.E. Plon, J.M. Murray, and G. van Haaften are equally 
contributing senior authors.
Conflict of interest: Baylor College of Medicine (BCM) and Miraca Holdings Inc. have 
formed a joint venture with shared ownership and governance of the Baylor Miraca Genet-
ics Laboratories, which performs exome sequencing. S.E. Plon is an employee of BCM and 
serves on the Scientific Advisory Board of Baylor Miraca Genetic Laboratory.
License: This work is licensed under the Creative Commons Attribution 4.0 Inter-
national License. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
Submitted: May 19, 2015; Accepted: May 12, 2016.
Reference information: J Clin Invest. 2016;126(8):2881–2892. doi:10.1172/JCI82890.
Downloaded from http://www.jci.org on August 15, 2016.   http://dx.doi.org/10.1172/JCI82890
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 8 8 2 jci.org   Volume 126   Number 8   August 2016
syndrome (PARDS) (16), their pulmonary status was complicat-
ed by pneumomediastinum, pneumothorax, and subcutaneous 
emphysema (Figure 1, C, D, F, and G).
Prior to these episodes, the children experienced feeding 
difficulties, failure to thrive, weight loss, mild psychomotor 
retardation, axial hypotonia, increased infection susceptibility 
ily 1; supplemental material available online with this article; 
doi:10.1172/JCI82890DS1). The affected individuals (referred 
to as affected individual A [GVH01] and B [GVH02]) died at the 
ages of 12 and 14 months, respectively, due to severe progressive 
irreversible lung damage following multiple virus-induced pneu-
monia episodes. After onset of pediatric acute respiratory distress 
Figure 1. Affected individuals with NSMCE3 mutations with severe lung disease immunodeficiency and chromosome breakage syndrome (LICS). (A) 
Pedigree of family 1. (B) Facial appearance of affected individual A (note the thin skin and prominent veins). (C) Chest X-ray of individual A, 4 days before 
admission at the PICU, showing severe PARDS consisting of bilateral alveolar infiltrates and (D) 14 days after admission, showing diffuse interstitial and 
alveolar infiltrates, pneumomediastinum, and subcutaneous emphysema. (E) Facial appearance of affected individual B. No dysmorphic facial features 
were noted. (F) Chest X-ray of individual B on admission at the PICU showing a predominantly right-sided alveolar infiltrate and (G) 18 days after admis-
sion showing severe PARDS complicated by pneumomediastinum, pneumothorax, and subcutaneous emphysema. (H) Pedigree of family 2. (I) Chest X-ray 
showing bilateral interstitial infiltrates of affected individuals C and D. (J) Corresponding chest CT scan at the level of the carina showing bilateral ground 
glass haziness with areas of consolidation and interposed air bronchogram. (K) Lung biopsy of individual D at day 6 showing patchy acute interstitial infil-
trates with lymphocyte predominance. In the areas of parenchymal injury, there was marked alveolar epithelial hyperplasia, consistent with early diffuse 
alveolar damage (original magnification, ×400). (L) Lung explant showing significant damage that includes overinflation, macroscopic cystic changes, and 
intracystic hemorrhage. (M) Schematic representation of the NSMCE3 protein with the identified missense mutations of the affected individuals. The 
homozygous mutations from the affected individuals from the Netherlands (NL; A and B) are indicated above and the compound heterozygous mutations 
from the affected individuals from the United States (US; C and D) are depicted below the figure.
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sequencing confirmed the homozygosity of variants in affected 
individuals and heterozygosity in the tested family members. 
The likely pathogenic variant results in a p.Leu264Phe missense 
change in NSMCE3 (NM_138704.3:c.790C>T) in a conserved 
region of the protein.
The c.790C>T variant has been detected in the heterozygous 
state among 662 individuals by the CLINSEQ project and anno-
tated as rs199905054 (17, 18). In the Genome of the Netherlands 
(GoNL) study, the variant has been observed in the heterozygous 
state 3 times in 500 unrelated individuals, indicating an allele 
frequency of 0.003 in the Netherlands (19), showing that the vari-
ant is not uncommon in the Dutch population. The heterozygous 
allele frequencies in the European and global population are 4.5 × 
10–5 and 2.5 × 10–5, respectively (Exome Aggregation Consortium 
[ExAC]; http://exac.broadinstitute.org, August 2015), with no 
homozygous individuals.
In a search of NSMCE3 using GeneMatcher (https://gene-
matcher.org/) (20), we identified a second family with a remark-
ably similar clinical history and research whole exome sequenc-
ing data in the United States. This family included an affected 
brother and sister (respectively, individual C [11179-05] and 
individual D [FCP488]), of healthy, unrelated parents of Europe-
an descent [FCP645 and FCP646]) (Figure 1H, Table 1, and Sup-
plemental Data, Family 2). Individual C presented with failure to 
thrive at 5 months of age, for which no apparent cause could be 
identified. At 14 months of age, he developed progressive, severe 
PARDS following infectious pneumonia that led to his death. 
Genetics consultation included a peripheral blood karyotype and 
multiple metabolic analyses without a diagnosis (Supplemental 
Data, Family 2). The autopsy findings revealed acute eosino-
(due to distinct B and T cell abnormalities), and eczema. Only 
mild or no dysmorphic features were noted (Figure 1, B and E, 
and Table 1). Karyotyping of cultured peripheral lymphocytes 
drawn either before (individual A) or during illness (individual B) 
revealed multiple de novo supernumerary marker chromosomes 
with or without additional de novo chromosome rearrangements 
(Supplemental Figure 2). Array comparative genomic hybridiza-
tion (aCGH) analysis of genomic DNA from blood did not show 
chromosome gains or losses, indicating the stochastic nature of 
the imbalances. Immunological analysis in individuals A and 
B showed that the numbers of T lymphocytes were low, but B 
lymphocytes and immunoglobulins were normal (except for 
increased IgM). Several specific antibody responses after vacci-
nation were low, and T lymphocyte proliferation after stimulation 
with recall antigens was absent or decreased (Table 2 and Supple-
mental Data, Family 1).
The unprecedented clinical and cytogenetic features observed 
in the patients prompted us to perform whole exome sequencing 
in this family. Sequencing of individuals A and B, parents, and an 
unaffected sibling yielded 110,896 non-reference positions found 
in at least one of the family members. Crosschecks with available 
databases revealed 63,734 variants not present in either dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/, build 134, August 2011) or 
our in-house database of 150 exomes. Homozygosity mapping 
and genealogic analysis showed evidence of distant-relatedness 
of the parents (see Methods). The largest homozygous region 
spanned 8.4 Mb (chr15:25,144,362-33,537,514 [GRCH38/hg38]; 
15q11.2–q13.3), and within this region one single, rare, and likely 
pathogenic variant was found: a homozygous G-to-A substitu-
tion at chr15:29268916 in the coding region of NSMCE3. Sanger 
Table 1. Phenotypical details of individuals affected by NSMCE3 chromosomal breakage syndrome
Patients NBS AT
Family 1 Family 2
A B C D
Common features
Small for gestational age + – – – + –
Failure to thrive + + ++ ++ + +
Facial features
Normocephaly + + + + – +
Microcephaly – – – – + –
Skin features
Eczema + + – – – –
Neurological features
Axial hypotonia + – – – – +
Increased infection susceptibility + + + + + –
Pulmonary features
Interstitial (eosinophilic) pneumonia + + + + – –
Multiple virus-induced pneumonia + + n.a. n.a. – –
Recurrent pneumonia – – – – + –
Thymic features
Thymic hypoplasia + n.a. + + + +
++, Present and severe; +, present; –, absent; n.a., not available.
Downloaded from http://www.jci.org on August 15, 2016.   http://dx.doi.org/10.1172/JCI82890
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 8 8 4 jci.org   Volume 126   Number 8   August 2016
from patients with ataxia telangiectasia (AT) (14% ± 17%). West-
ern blot analysis showed a 48% reduction in ATM protein com-
pared with the 85% reduction seen in patients with AT.
Research exome sequencing of individual D and both parents 
revealed 24,500 germline variants. Because of the suspected 
autosomal recessive inheritance pattern, variants were filtered 
according to homozygosity and compound heterozygosity. No 
rare or novel homozygous coding variants (segregating in the 
parents) were identified. Two genes with rare compound hetero-
zygous coding variants were identified: INPP5J and NSMCE3. 
However, both missense variants in INPP5J were predicted to be 
benign by Polymorphism Phenotyping v2 (PolyPhen-2; http://
genetics.bwh.harvard.edu/pph2/), and no rare variants were 
observed in INPP5J in the Dutch family (individuals A and B), 
despite good coverage. Two missense and likely pathogenic vari-
ants in NSMCE3 were found (Figure 1M), consisting of a mater-
nally inherited p.Leu264Phe (NM_138704.3:c.790C>T) change 
(identical to individuals A and B) and a paternally derived G-to-A 
substitution resulting in a p.Pro209Leu change. Both variants 
were confirmed by Sanger sequencing. Directed Sanger analysis 
of DNA from lung tissue from the sibling, individual C, demon-
strated both alleles. The p.Pro209Leu mutation was predicted 
“possibly damaging” by PolyPhen-2 (0.752) and deleterious by 
SIFT (0.03; http://sift.jcvi.org/) and is absent in the ExAC data-
base, despite good coverage at that position.
Our genetic studies of 2 unrelated kindreds with remarkably 
similar clinical histories provide a strong link between missense 
mutations in NSMCE3 and the phenotypes of chromosomal insta-
philic pneumonia, diffuse alveolar damage, extensive lobular 
fibrosis, bronchiolitis obliterans, and organizing pneumonia. 
Individual D, who also presented with significant growth restric-
tion, developed severe pneumonitis at the age of 13 months 
and needed prolonged mechanical ventilation (Figure 1, I and 
J). Lung biopsy showed patchy acute interstitial infiltrates with 
lymphocyte predominance (Figure 1K). She underwent cadav-
eric lung transplantation at 15 months of age because of severe 
pulmonary damage initially resembling PARDS. The histopa-
thology of her explanted lungs revealed end-stage lung disease 
due to organizing pneumonia with extensive lobular remodeling, 
obliteration of air spaces, interstitial fibroplasia, cystic remod-
eling and marked hyperinflation, and patchy interstitial hemor-
rhage (Figure 1L). Within the following year, she developed bone 
marrow failure and increased infection susceptibility, including 
sternal osteomyelitis. Her clinical status deteriorated, and indi-
vidual D died at 32 months of age. Peripheral blood karyotype 
in lymphocytes of individual C at 6 months of age and when not 
acutely ill showed a normal (46,XY) karyotype, and in individu-
al D breaks at 3p13~14 were identified in 2 of 28 examined cells. 
Metaphase spreads from 100 early-passage fibroblasts from 
individual D showed stochastic chromosome rearrangements 
in 13 cells (Supplemental Figure 2). Both affected individuals, C 
and D, showed diminished T cell percentage and an increased 
B cell percentage around 13 months of age (Table 2). A clinical 
radiosensitivity assay of lymphocytes (21) from individual D 
demonstrated increased sensitivity to 1 Gy of ionizing radiation 
(IR; 16% survival with normal range 50% ± 13%), similar to cells 
Table 2. Immunological features of NSMCE3 chromosomal breakage syndrome
Patients NBS AT
Family 1 Family 2
A B C D
Immunological features
IgA and IgG Immunoglobulin levels = = n.a. ↑ ↓ ↓
IgM immunoglobulin levels ↑ ↑ n.a. ↑ = = or ↑
IgE immunoglobulin levels = = n.a. ↑ = = or ↓
T cells
CD4+ levels n.a. ↓ ↓ ↓ ↓ ↓
CD8+ levels n.a. ↓ ↓ ↓ ↓ ↓
T cell proliferation test to mitogens
Phytohemagglutinin ↓ ↓ n.a. = ↓ ↓
Concanavalin A ↓ ↓ n.a. = ↓ ↓
Pokeweed ↓ ↓ n.a. = ↓ ↓
Tetanus ↓↓↓ ↓↓↓ n.a. ↓↓↓ ↓ ↓
Candida ↓↓↓ ↓↓↓ n.a. ↓↓↓ ↓ ↓
B cells = ↓ ↑ ↑ ↓ =
Antibody titers to
Diphtheria = = n.a. = = or ↓ ↓
Pneumococcal vaccination ↓ ↓ n.a. ↑ = or ↓ ↓↓↓
Delayed type hypersensitivity testing
Tetanus ↓↓↓ ↓↓↓ n.a. ↓↓↓ ↓ ↓
Candida ↓↓↓ ↓↓↓ n.a. ↓↓↓ ↓ ↓
=, normal; ↑, increased; ↓, lowered; ↓↓↓, absent; n.a., not available.
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Figure 2. NSMCE3 mutations destabilize the SMC5/6 complex. (A) Schematic of the SMC5/6 complex. (B) Structure of NSMCE1/NSMCE3, highlighting 
the positions of the Leu264Phe (L264F) and Pro209Leu (P209L) mutants that destabilize the WH/B subdomain of NSMCE3. Loops missing from the 
deposited structure were modelled and are shown in gray (24). (C) Yeast 2-hybrid analysis showing interactions between NSMCE3 and NSMCE1 or NSMCE4, 
scored on His– plates containing 5 mM 3-amino-1,2,4-triazol (-LTH). WT denotes WT NSMCE3; L97A: NSMCE3 Leu97Ala, which abrogates NSMCE1 binding 
(25); F266A: NSMCE3 Phe266Ala, which reduces binding to NSMCE4 (21). L264F only interacts with NSMCE1; P209L has reduced interaction with NSMCE1 
and no interaction with NSMCE4. Controls: c1, BD-NSMCE3 with empty AD vector; c2, empty BD vector with AD-NSMCE4 (top) or NSMCE1 (bottom). (D) 
NSMCE1 and His-tagged NSMCE3 (WT, P209L, and L264F were coexpressed in, and purified from, E. coli. Left: Coomassie-stained SDS-PAGE shows copu-
rification of NSMCE1 and NSMCE3. Right: Immunodetection of His-tagged NSMCE3. P209L is unstable; L264F is more stable. (E) Size exclusion chroma-
tography column. NSMCE1 and NSMCE3 co-elute, forming a stable complex. NSMCE1 and L264F co-elute, over a broader range of volume and non-uniform 
distribution, indicating either unfolding of L264F or interaction with the chromatography resin. (F) GFP-tagged NSMCE3 (WT or L264F) and Myc-tagged 
NSMCE1 were ectopically expressed in human U20S osteosarcoma cells; proteins were stable and full length in input samples. Proteins were immunopu-
rified using anti-GFP beads. Purification of NSMCE1 was reduced when copurified with L264F, which indicated reduced affinity. (G) GFP-tagged NSMCE3 
(WT or L264F) was ectopically expressed in U20S cells. Proteins were immunopurified using anti-GFP beads. Reduced copurification indicates a compro-
mised integration of the mutated NSMCE3 into the SMC5/6 complex. (H) Western blot analysis of SMC5/6. NSMCE3 is undetectable in fibroblasts from 
individual B (GVH02) and individual D (FCP488) compared with primary fibroblast cell lines (48BR and GM05757). High exposure of anti-SMC5 blot shows 
reduction of SMC5. Levels of both SMC5 and SM6 were reduced in patient fibroblasts, indicating destabilization of the complex. Loading control: tubulin.
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bility and failure to thrive with infectious (viral) pneumonia end-
ing in fatal lung disease. Together with the rarity of the variants 
and the predicted damaging effect at the protein level, these data 
suggest the identification of a chromosome breakage disease due 
to alteration of the NSMCE3 component of the SMC5/6 complex, 
which is essential for responses to DNA damage and chromosome 
segregation during cell division.
NSMCE3 mutant proteins destabilize the SMC5/6 com-
plex. Within the SMC5/6 complex the interaction of NSMCE1, 
NSMCE3, and NSMCE4 is essential for the formation of a tight 
subcomplex (22–24), which bridges the large SMC5 and SMC6 
subunits (refs. 23, 24, and Figure 2A). NSMCE3 interacts with 
NSMCE1 through its N-terminal winged-helix (WH) domain, 
WH/A, and with NSMCE4 via its C-terminal WH domain, WH/B 
(22–24). We studied the effect of the 2 variants, p.Pro209Leu and 
p.Leu264Phe, found in the 4 affected individuals on NSMCE3 
interactions within the SMC5/6 protein complex. p.Pro209Leu 
is found within the C-terminal WH/B and p.Leu264Phe in the 
WH/B “extension” (WH/B-e) subdomains of the protein (Fig-
ure 2B). The destabilizing effect of both mutations is predict-
ed by computational analyses of models based on the crystal 
structure of the NSMCE1-NSMCE3 dimer (Protein Data Bank 
[PDB] ID 3NW0; http://www.rcsb.org) (ref. 25 and Figure 2B). 
Leu264Phe is predicted to disrupt fold in the NSMCE3 WH/B-e 
domain because of steric clashes with side chains on the adja-
cent helix, whereas Pro209 ends the preceding helical element, 
so the Pro209Leu mutation is likely to disrupt the secondary 
structure of the protein.
Figure 3. Cellular defects resulting from destabilization of SMC5/6. (A) Example of micronuclei (indicated by arrows) and quantification of percentage of 
cells with micronuclei in fibroblasts from individual B (GVH02), control fibroblasts (1BR and 48BR), and an individual with ATM (AT1BR). Scale bar: 50 μm. 
(B) Survival of primary fibroblasts from individual B (GVH02) compared with the control 48BR fibroblasts after treatment with MMS, IR, CPT and UV light 
shows a modest sensitivity to all agents. (C) Analysis of γH2AX foci after IR in either G1 or G2. Control (48BR), affected individual B (GVH02), ATM (AT1BR), 
and BRCA2 (HSC62) fibroblasts were irradiated with 3 Gy IR and incubated for the designated times before fixing and mounting. ATM–/– cells showed a 
defect in the slow repair fraction in both G1 and G2. Cells of individual B, like HR-defective BRCA2 cells, show a defect in G2. (D) Representative example 
of EdU-positive cells scored in E. Left: DAPI; middle: EdU; right: merge. Scale bars: 20 μm. (E) HU recovery assay. Normal (48BR) or individual B’s (GVH02) 
fibroblasts were incubated for 18 hours either with or without 250 μM HU. HU was removed, and the number of cells incorporating EdU (thymidine analog) 
in the following 30 minutes was analyzed. (F) Complementation of the HU recovery defect. Individual B’s (GVH02) primary fibroblasts were transfected 
with GFP-tagged normal (NSMCE3 WT) or Leu264Phe variant NSMCE3 (NSMCE3 L264F) cDNA or empty vector (eGFP). The cells were treated with or with-
out HU after 48 hours, and the number of transfected cells (identified by GFP fluorescence) that incorporated EdU was assessed. Results shown in A–C 
and E and F represent mean ± SD of 3 experiments. *P < 0.05, Student’s t test, 2-tailed.
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To determine the effect of the patient mutations on the inter-
actions between NSMCE3 and NSMCE1 or NSMCE4, we first used 
yeast 2-hybrid studies to compare the Leu264Phe and Pro209Leu 
missense mutations with 2 previously characterized NSMCE3 
mutants (Leu97Ala and Phe266Ala) as controls. Leu97Ala struc-
turally perturbs the WH/A subdomain of NSMCE3, which inter-
acts with NSMCE1 (26), whereas Phe266Ala perturbs the WH/B 
subdomain, which interacts with NSCME4 (22). The Leu264Phe 
mutation of the affected individuals A–D abolished binding of 
NSMCE3 to NSMCE4, while its interaction with NSMCE1 was 
only mildly affected. The Pro209Leu mutation of the affected 
individuals C and D, as well as abolishing the NSMCE4 interac-
tion, also drastically reduced the NSMCE1 interaction, confirm-
ing that both missense changes directly affect the structure of the 
WH/B and WH/B-e subdomains (Figure 2C).
Next we purified recombinant human NSMCE1 and NSMCE3 
proteins coexpressed in E. coli. Both the WT and Leu264Phe forms 
of NSMCE3 co-purified in a roughly 1:1 stoichiometric ratio with 
(untagged) NSCME1. The Pro209Leu variant, however, proved to 
be highly prone to C-terminal truncation (as judged by Western 
blot analysis), resulting in a species migrating on SDS-PAGE gels 
with a smaller molecular mass. This species corresponded to just 
the N-terminal WH/A subdomain of NSMCE3 (Figure 2D), and 
this variant was not analyzed further. Size-exclusion chromatog-
raphy using the purified recombinant proteins showed NSMCE1 
and NSMCE3 to form a stable dimer. The Leu264Phe variant still 
interacts and co-elutes with NSMCE1, but elutes over a much 
broader volume and with a non-uniform distribution (Figure 2E). 
It is likely that unfolding of the WH/B-e subdomain promotes 
direct nonspecific interactions with the chromatography resin.
To investigate the stability of the Leu264Phe variant in 
human cells, we coexpressed WT NSMCE3 and the Leu264Phe 
NSMCE3 variant with NSMCE1 in human U2OS cells. Both WT 
and variant NSMCE3 proteins were expressed to similar levels 
and were stable. Coimmunoprecipitation showed that the inter-
action between NSMCE1 and the variant NSMCE3 Leu264Phe 
was slightly reduced (Figure 2F). Consistent with the destabi-
lization of the complex seen in patient cells, the Leu264Phe 
variant showed reduced incorporation into the native SMC5/6 
complex (Figure 2G).
Finally, we investigated the effect of the weakened inter-
actions of the mutant NSMCE3 proteins on the endogenous 
SMC5/6 complex in primary fibroblasts of 1 affected individual 
from each kindred (individuals B and D). NSMCE3 levels in both 
patient fibroblasts were dramatically reduced to levels that were 
below the level of detection in our assay. In addition to NSMCE3, 
levels of the complex subunits SMC5 and SMC6 were also sig-
nificantly reduced, indicating that the stability of the SMC5/6 
protein complex is compromised in affected individuals of both 
kindreds (Figure 2H). Together these data show that the identi-
fied missense variants in NSMCE3 destabilize NSMCE3 and the 
SMC5/6 complex.
Cells of affected individuals exhibit increased cellular sensitivity 
to genotoxins and defective homologous recombination. Studies in 
a range of organisms have shown that mutations in components 
of the SMC5/6 complex confer genome instability, and sensitivi-
ty to DNA damaging agents and particularly to replication stress 
(7, 27–29). Early-passage primary fibroblasts from individual B 
(homozygous for the Leu264Phe variant) exhibited significantly 
increased levels of micronuclei, a finding that indicates genome 
instability and is consistent with increased chromosome break-
age. Approximately 20% of cells contained micronuclei, which is 
similar to levels seen in ATM fibroblasts (Figure 3A) and to cells 
with mutations in NSMCE2, which encodes another component 
of the SMC5/6 complex (10).
We exposed fibroblasts from individual B to a variety of dam-
aging agents and compared their sensitivities to those of normal 
cells (Figure 3B). We found modest, but reproducible, hyper-
sensitivity to different agents that produce different types of 
DNA damage (double-strand breaks [DSBs], methylated bases, 
topoisomerase-induced breaks and base damage, respectively). 
Analysis of γH2AX foci, a surrogate marker for DNA damage, 
showed that repair kinetics in G1 cells were unaffected, consistent 
with proficient nonhomologous end joining (NHEJ). However, 
similar to homologous recombination–defective (HR-defective) 
BRCA2–/– cells, individual B’s fibroblasts had a defect in the slow 
repair fraction in G2 (Figure 3C), consistent with a defect in HR 
(30). HR is required to stabilize stalled forks and rescue replica-
tion (31). Consistently, in multiple experiments, the most dra-
matically altered response was seen in response to hydroxyurea 
(HU), a DNA replication inhibitor. After release of the HU block, 
DNA replication recovered rapidly and completely in normal 
fibroblasts, as evidenced by incorporation of 5-ethynyl-2′-deoxy-
uridine (EdU), but not in the fibroblasts of the affected individ-
ual (Figure 3, D and E), even though similar levels of cells were 
arrested in S phase (Supplemental Figure 3). This defect in recov-
ery from replication stress is similar to that in NSMCE2-defec-
tive cells (10). The defect was restored by expression of normal 
NSMCE3 protein but not with the mutant protein (p.Leu264Phe), 
thus confirming that the replication recovery defect results from 
the NSMCE3 mutation (Figure 3F).
Discussion
Here, we identify homozygous and compound heterozygous mis-
sense mutations in NSMCE3 as the cause of what we believe to 
be a new autosomal recessive chromosome breakage syndrome, 
characterized by failure to thrive, absent (or mild) dysmorphic 
features, immune deficiency, and severe and eventually fatal 
pediatric pulmonary disease, initially resembling PARDS, in early 
childhood. The proposed disease name is lung disease immuno-
deficiency and chromosome breakage syndrome (LICS). Lym-
phocytes of affected individuals showed increased chromosomal 
breakage, and fibroblasts were sensitive to DNA-damaging agents. 
The underlying lymphocyte proliferation defect is consistent with 
the destabilization of the SMC5/6 complex seen in fibroblasts and 
consequential defect in HR (32).
Both of the NSMCE3 missense mutations identified in 
these kindreds destabilize NSMCE3. Levels of NSMCE3 were 
below detection levels in fibroblasts from affected individuals 
B (homozygous p.Leu264Phe) and D (compound heterozygote 
p.Leu264Phe, p.Pro209Leu). This could be due to lack of expres-
sion of NSMCE3, but, since loss of SMC6 or NSMCE2 is lethal in 
early embryonic mice (33, 34), it is likely that NSMCE3 is present 
at low levels in the patient cells but below the detection level of our 
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in AT and NBS (39). Common respiratory tract viruses were iso-
lated at the beginning, but no longer found during follow-up in 
individual B, indicating intactness of at least part of the cyto-
toxic immune response. This is consistent with the laboratory 
evaluations excluding SCID, but instead pointing to a distinct, 
combined T and B cell immunodeficiency. The fact that in the 4 
affected individuals B cell counts were normal indicates proper 
efflux from the bone marrow, which is defective in AT and NBS 
(40, 41). This normal efflux would fit with the normal NHEJ, and 
hence normal V(D)J recombination, shown in the cells from the 
subjects reported here.
The poor antibody responses to specific vaccinations as well 
the decreased recall antigen proliferation are also seen in NBS 
(40). This effect has previously been attributed both to an absolute 
decrease in the number of B lymphocytes and to a reduced propor-
tion of switched memory B lymphocytes secondary to defective 
V(D)J and class switch recombination (CSR) (40), respectively. In 
patients with AT, the disturbed naive B cell and T cell homeosta-
sis has been related to reduced B and T cell production caused by 
disturbed V(D)J recombination. This defect also leads to a limited 
B cell and T cell receptor repertoire (41). In the 4 affected individu-
als described here, B lymphocyte levels were normal, and no signs 
of a defective V(D)J recombination defect were present.
Although it has previously been shown that HR is neces-
sary for normal B cell lymphocyte development (32), data from 
our patients suggest an important role for HR in normal T cell 
development. The decreased T cell counts could alternatively 
be indicative of increased apoptosis or defective thymic output, 
which could well fit the thymic hypo- and aplasia observed in 
patients A and D and which had also been described in AT (41) 
and NBS (42).
Despite extensive attempts by investigators in both the United 
States and European centers, we were unable to identify clinically 
similar patients prior to the identification of these 2 kindreds by 
the use of GeneMatcher. This highlights the importance of data 
sharing through GeneMatcher and other avenues being developed 
by the Matchmaker Exchange of the Global Alliance for Genomics 
and Health (43). However, the carrier incidence, especially in the 
Netherlands, would predict the existence of several other cases. 
The fact that no other patients were identified presumes that, so 
far, these patients have remained undiagnosed. For the 2 families 
reported here, suspicion of an underlying chromosome instability 
syndrome occurred only after a similar disease history was noted 
in a second sibling. Prior to the rapid onset of fatal pulmonary dis-
ease, clinical symptoms of individuals affected by this breakage 
syndrome were relatively mild and could not be classified. Clini-
cal assays, such as karyotyping and IR sensitivity, could be abnor-
mal and can be early indicators of the syndrome. We recommend 
development of a clinical assay for the replication recovery defect 
and for NSMCE3 mutations and consideration of this disorder for 
children with unexplained, rapid pulmonary failure following mul-
tiple virus-induced pneumonias.
In summary, our work describes what we believe to be a novel 
autosomal recessive chromosome breakage syndrome, resulting 
from missense mutations in NSMCE3. These mutations affect 
the stability of the SMC5/6 complex and HR, leading to defects in 
the function of T and B cell lymphocytes. This disorder, designat-
antibodies. The levels of SMC5 and SMC6 were also significantly 
reduced, showing the complex to be destabilized. In vitro anal-
ysis suggests that Pro209Leu leads to C-terminal truncation of 
NSMCE3. In contrast, the Leu264Phe variant, while still forming 
a complex with NSMCE1, has a reduced interaction with NSMCE4 
and SMC6. The destabilization of the SMC5/6 complex is much 
more severe than the mild effect seen in cells from individuals 
with a truncating mutation in NSMCE2, encoding the SUMO 
ligase subunit of SMC5/6 (10). Since NSMCE2 SUMO ligase activ-
ity is not required for all SMC5/6 functions (34), this may explain 
the differences in clinical features. As both mutations in NSMCE3 
disrupt the interaction with NSMCE4, we speculate that such 
mutations specifically result in the pulmonary phenotype that we 
have observed. Additional phenotype and genotype data are nec-
essary to further evaluate this hypothesis.
In cells from affected individual B, the destabilization of the 
SMC5/6 complex resulted in defective DNA repair by HR but not 
by NHEJ. This is consistent with previous findings in the literature 
(4, 6, 7, 28, 35). Consistent with the HR defect, fibroblasts of affect-
ed individual B had a defect in the recovery from replication stress, 
which could be complemented by expression of WT NSMCE3 but 
not p.Leu264Phe, showing the defect to be a direct consequence 
of the mutation. The lack of recovery from replication stress is also 
seen in cells mutated in NSMCE2 (10), showing it to be a common 
consequence of misregulation of the SMC5/6 complex.
The affected individuals share some clinical features with 
individuals with Nijmegen breakage syndrome (NBS) and AT 
chromosomal breakage syndrome (Tables 1 and 2). In NBS, the 
affected protein, nibrin, along with MRE11 and RAD50, forms 
the MRN complex, which is required for DSB repair (both NHEJ 
and HR) (36) and together with ATM, the protein mutated in AT, 
is necessary for proper ATM-mediated DNA damage signaling 
response to DSBs (36, 37).
In the syndrome associated with mutations in NSMCE2, lin-
ear growth, weight, and head circumference growth were severely 
impaired (10). In the affected individuals described here, linear 
growth and weight were slightly affected in individuals A and B, 
but more severely affected in individuals C and D. This difference 
might be explained by the more severe effect of p.Pro209Leu, 
present in the latter 2 affected individuals. Deregulation of glu-
cose metabolism, observed in AT as well as in the NSMCE2-asso-
ciated syndrome (10), was not noted in the affected individuals 
described here prior to their illness. During their stay at the pedi-
atric intensive care unit (PICU), individuals A and B had (slightly) 
elevated glucose plasma levels, a feature commonly seen during 
critical illness (38). No insulin plasma levels were measured to cor-
relate with glucose levels to provide further insight into the pos-
sible presence of insulin resistance. No abnormalities in glucose 
regulation have been noted in individuals C and D.
No malignancies were reported in these 4 affected individu-
als, including autopsy analysis of individuals A, C, and D, in con-
trast to patients with AT and NBS. However, the death of all 4 chil-
dren in very early childhood would obscure any predisposition to 
cancer. Bone marrow failure was reported in individual D after she 
received a lung transplant, shortly before death.
The increased susceptibility to specific infections and specif-
ic allergens in the 4 affected individuals have also been observed 
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the affected children or regions overlapping between affected and 
unaffected family members with different start and end points were 
considered for further analysis. Regions overlapping gene deserts 
around centromeres were excluded.
Micronuclei protocol. Fibroblasts were grown to approximate-
ly 70% confluence, trypsinized, resuspended, counted, and seeded 
onto glass coverslips. Twenty-four hours later, cells were fixed using 
4% paraformaldehyde (PFA) for 10 minutes at room temperature. 
Cells were then mounted on glass slides using ProLong Gold Antifade 
Mountant with DAPI (Life Technologies). Approximately 1,000 cells 
were analyzed over 3 independent experiments.
Clonogenic survival assays. Clonogenic survival assays were carried 
out as described previously by Arlett et al. (47, 48). Cells were plated in 
triplicate on 10-cm dishes with feeder cells (1BR normal donor fibro-
blasts) after treatment with indicated doses of DNA-damaging agent 
(HU: 0, 0.25, 1, 5 mM for 18 hours; camptothecin [CPT]: 0, 100, 300, 
500 nM for 1 hour; methyl methanesulfonate [MMS]: 50, 100, 150, 
200, 250 μg/ml for 1 hour; IR: 0, 1, 3, 5, 7, 10 Gy; UV: 0, 2, 5, 7, 10 
Jm–2). Feeder cells were irradiated with 35 Gy γ-rays. After treatment, 
cells were washed with PBS, supplied with fresh prewarmed media, 
and incubated at 37°C with 5% CO2 for 21 days until the formation of 
macroscopic colonies. After 21 days, cells were treated with 1 ml 10% 
methylene blue in 10 ml media. Survival was calculated by dividing 
the average number of colonies on treated plates by the average num-
ber of colonies on untreated plates, correcting for plating efficiencies. 
Data are the mean ± SD of 3 biological replicates.
Repair pathway assay. DNA repair pathway defects were investi-
gated by monitoring the rate of decline in γH2AX foci as a surrogate 
marker for recovery after IR in G1 or G2 phases of the cell cycle (30). 
NHEJ is the major DSB repair pathway in both G1 and G2, and HR is 
only required for repair of about 15% of IR-induced DSBs in G2. Con-
sistent with this, BRCA2-deficient cells, defective in HR, are only 
defective in the slow recovery fraction in G2 cells, but ATM–/– cells are 
defective in both G1 and G2 (30).
Cell culture and irradiation. Primary fibroblasts from 48BR (WT 
control), GVH02 (NSMCE3-L264F), HSC62 (BRCA2-deficient pri-
mary human fibroblasts from a patient with a homozygous mutation 
in BRCA2; ref. 49), and AT1BR (ATM–/–) were grown in MEM supple-
mented with 15% fetal calf serum, 2 mM l-glutamine, 100 IU ml pen-
icillin, and 100 μg/ml streptomycin.
Cells were grown in 35-mm dishes on glass coverslips for 48 
hours before being irradiated using a 137Cs γ-ray source at a dose rate 
of 1 Gy per 9 seconds and exposed for 27 seconds. Cells were fixed 
using 4% PFA, permeabilized with 0.2% Triton X-100, and washed 
with PBS. Cells were incubated with primary antibodies for 30 min-
utes and washed 3 times with PBS before 20 minutes of incubation 
with secondary antibodies. Slides were mounted using ProLong Gold 
Antifade Mountant (Life Technologies) containing DAPI and cells 
imaged using an IX73 Olympus microscope, equipped with a Lumen-
cor LED light source, a 60× 1.4NA PlanApo lens (Olympus), and an 
Orca Flash CMOS camera (Hamamatsu). Images were analyzed using 
Micro-Manager and ImageJ (NIH) software (50, 51). Scoring of foci 
was performed until at least 15 G2 cells and 15 G1 cells were registered 
per sample. Experiments were performed in triplicate, and error bars 
represent the SD between 3 independent experiments and between 2 
operators. Statistical analysis using Student’s t test was performed at 
critical time points to evaluate the significance of differences in levels 
ed LICS, which expands the spectrum of chromosomal breakage 
syndromes, is associated with progressive, severe PARDS follow-
ing viral pneumonia, resulting in death in early childhood of the 
affected individuals described here.
Methods
Research subjects. Genomic DNA from the affected individuals and 
family members was extracted from peripheral blood using stan-
dard methods.
Genealogy and pedigree construction, family 1. Birth, marriage, 
and death records, personal cards of the Dutch civil registration 
(years 1811–2013), and church books (before 1811) were used for 
pedigree construction.
Blood and fibroblast samples. The blood samples used for karyotyp-
ing in lymphocytes of individual A were drawn at the age of 9 months 
and at the age of 12.5 months, when she presented with severe pul-
monary insufficiency, during her stay at the PICU. The cultures of 
dermal fibroblasts were taken from individual A (at the beginning and 
the end) at the PICU only. The blood sample used for karyotyping in 
lymphocytes and the culture for dermal fibroblasts from individual B 
were taken during her stay at the PICU only at the age of 14 months. 
The blood sample used for karyotyping in lymphocytes of individuals 
C and D was performed on peripheral blood lymphocytes at the ages 
of, respectively, 6 months and 2 years and 5 months.
Genetic and cytogenetic analysis. Karyotyping of short-term cul-
tures of stimulated peripheral blood lymphocytes and dermal fibro-
blasts, sequencing of candidate genes, and aCGH (BlueGnome 
Cytochip v2.0 [individual A] and Agilent 180K oligonucleotide plat-
form [patient B]) based on DNA from blood were all performed in a 
clinical diagnostic setting according to standard procedures. Exome 
sequencing was performed as described previously for the Dutch kin-
dred (44) and for the US kindred (45). The variants were deposited 
to ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/; SCV000266831 
and SCV000266832), exome sequencing data within the 8.4-Mb 
homozygous region of the Dutch kindred were deposited to the 
European Genome-phenome Archive (https://www.ebi.ac.uk/ega/
home; EGAS00001001786). Testing of candidate genes and meth-
ylation-specific multiplex ligation-dependent probe amplification 
(MS-MLPA) were performed in a clinical diagnostic setting. Karyo-
typing in lymphocytes was performed by G-banding at 500–550 band 
resolution. Testing of skin fibroblasts for sensitivity to radiation and to 
mitomycin C followed standard clinical diagnostic procedures. aCGH 
based on DNA from peripheral blood was performed using either 
BlueGnome Cytochip v2.0 (individual A) or the Agilent 180K oligonu-
cleotide platform (individual B) following instructions provided by the 
manufacturer. As a reference DNA sample, a mixture of genomic DNA 
from 50 normal, healthy females was used.
Homozygosity mapping. Genomic DNA samples from both 
patients in family 1, their parents, and 2 of the unaffected siblings 
were analyzed using Illumina HumanCytoSNP-12v2 arrays accord-
ing to the protocol of the manufacturer (Illumina). Regions of homo-
zygosity were determined using BeadStudio software. Windows of at 
least 20 homozygous SNPs were detected for each tested individual; 
no mismatches were allowed. Homozygous regions with the same 
start and end points present in both patients or in any of the unaf-
fected family members were excluded on the basis of the identity 
by descent (IBD) premise (46). Only regions exclusively present in 
Downloaded from http://www.jci.org on August 15, 2016.   http://dx.doi.org/10.1172/JCI82890
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 8 9 0 jci.org   Volume 126   Number 8   August 2016
for 10 minutes, and NaCl concentration was adjusted to 150 mM 
for coimmunoprecipitation to examine protein-protein interaction. 
Lysate was added to GFP-Trap_MA beads (ChromoTek), followed by 
rolling at 4°C for 2 hours. Beads were washed 4 times with wash buffer 
(20 mM HEPES, pH 7.4, 150 mM) and then resuspended in SDS load-
ing buffer for analyses by immunoblotting.
Protein assays. For size exclusion, NSMCE1 and NSMCE3 were 
coexpressed in and purified from E. coli (23). The resulting com-
plex was applied to a Superdex 200 Increase 5/150 GL column (GE 
Healthcare), preequilibrated in 20 mM HEPES.NaOH pH 7.5, 250 
mM NaCl, 0.5 mM TCEP.
Yeast 2-hybrid studies. The NSMCE3 Pro209Leu and Leu264Phe 
mutations were compared with 2 previously characterized NSMCE3 
mutants as controls (21, 25). Yeast 2-hybrid plasmids expressing 
NSMCE3, either WT or the mutated form as indicated, fused to the 
Gal4 DNA-binding domain or the empty vector control, and WT 
NSMCE1 or NSMCE4 fused to the Gal4-activation domain, were 
coexpressed in yeast cells, which were subsequently plated on the 
indicated media and grown at 30°C as described previously (22).
Statistics. All numerical data were analyzed using parametric sta-
tistical tests, namely Student’s t test, type 1, with 2 tails, and P values 
less than 0.05 were considered significant. All tests used and thresh-
olds for significance are indicated in the figure legends.
Study approval. Informed consent was obtained from both partici-
pating families through studies approved by the Medical Ethical Com-
mittee of the University Medical Center Utrecht and the Institutional 
Review Board of Baylor College of Medicine. Parents of the children in 
family 1 provided written consent for the publication of photographs of 
the affected individuals.
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